Cooper Companies reported its quarterly earnings results that surpassed analysts’ expectations.
The medical device company’s earnings came in at $3.24 a share for the quarter, above the Zacks’ consensus estimate of $3.10. The figure was $3.17 per share a year ago.
Cooper Companies revenue rose +15.7% from the year-ago quarter to $787.20 million, also exceeding analyst estimates of $739.30 million.
Looking ahead, Cooper expects its FY 2022 earnings in the range of $13.700-$14.200, and FY22 earnings of $13.70-$14.20 EPS.
COO saw its Momentum Indicator move below the 0 level on May 23, 2023. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In of the 85 cases, the stock moved further down in the following days. The odds of a decline are at .
COO moved below its 50-day moving average on May 25, 2023 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for COO crossed bearishly below the 50-day moving average on June 02, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The RSI Indicator entered the oversold zone -- be on the watch for COO's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where COO advanced for three days, in of 354 cases, the price rose further within the following month. The odds of a continued upward trend are .
COO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 317 cases where COO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock slightly better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. COO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.389) is normal, around the industry mean (25.286). P/E Ratio (61.350) is within average values for comparable stocks, (143.072). Projected Growth (PEG Ratio) (2.968) is also within normal values, averaging (5.656). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (5.163) is also within normal values, averaging (53.674).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a maker of medical devices
A.I.dvisor indicates that over the last year, COO has been closely correlated with IDXX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if COO jumps, then IDXX could also see price increases.
|IDXX - COO|
|SYK - COO|
|RVTY - COO|
|ISRG - COO|
|ZBH - COO|